CDK11A: A Potential Drug Target and Biomarker for Cancer (G728642)

Target Name: CDK11A

NCBI ID: G728642

CDK11A

CDK11A: A Potential Drug Target and Biomarker for Cancer

Cyclin dependent kinase 11A (CDK11A) is a key regulator of cell cycle progression and has been implicated in various cellular processes, including cell growth, apoptosis, and differentiation. CDK11A is a protein that plays a crucial role in the control of mitosis, as it is involved in the regulation of the mitotic spindle formation and the metaphase transition. Moreover, CDK11A is a potent inhibitor of cell growth, and its overexpression has been shown to promote tumorigenesis. Therefore, targeting CDK11A has potential as a drug or biomarker for cancer treatment.

CDK11A Expression and Cancer

CDK11A is a widely expressed protein and is found in various tissues, including muscle, pancreas, and breast tissue. In cancer, CDK11A is often overexpressed and is associated with poor prognosis. For example, a study by Kim et al. found that CDK11A was overexpressed in various cancer types, including breast, lung, and ovarian cancer. Additionally, CDK11A has been shown to promote the growth and survival of various cancer cell lines, including breast and ovarian cancer cells.

CDK11A as a Drug Target

CDK11A has been identified as a potential drug target due to its unique mechanism of action and its involvement in various cellular processes. One of the main reasons for its potential as a drug target is its involvement in cell growth and apoptosis. CDK11A is a potent inhibitor of cell growth and has been shown to inhibit the growth of various cancer cell lines in a dose-dependent manner. Additionally, CDK11A has been shown to induce cell apoptosis in various cell lines and models, including cancer cells.

Another potential mechanism for CDK11A as a drug target is its involvement in the regulation of mitosis. CDK11A is involved in the regulation of mitosis at different stages, including metaphase, anaphase, and telophase. Therefore, targeting CDK11A may be a useful strategy for cancer treatment.

CDK11A as a Biomarker

CDK11A has also been identified as a potential biomarker for cancer. Several studies have shown that CDK11A is expressed in various cancer types, including breast, lung, and ovarian cancer. Additionally, some studies have shown that CDK11A has the potential to serve as a biomarker for cancer, as its expression has been associated with poor prognosis in cancer patients.

CDK11A has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and differentiation. Therefore, its expression may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Conclusion

CDK11A is a protein that plays a crucial role in the regulation of cell cycle progression and has been implicated in various cellular processes, including cell growth, apoptosis, and differentiation. Its overexpression is associated with poor prognosis in cancer and its inhibition has the potential as a drug or biomarker for cancer treatment. Further studies are needed to fully understand the role of CDK11A in cancer and its potential as a drug or biomarker.

Protein Name: Cyclin Dependent Kinase 11A

Functions: Appears to play multiple roles in cell cycle progression, cytokinesis and apoptosis. The p110 isoforms have been suggested to be involved in pre-mRNA splicing, potentially by phosphorylating the splicing protein SFRS7. The p58 isoform may act as a negative regulator of normal cell cycle progression

The "CDK11A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDK11A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets